Jefferies notes that Eli Lilly’s (LLY) tirzepatide’s 52-week fibrosis improvement in SYNERGY-NASH hit the firm’s bull case based on the EASL abstract and that it is “becoming more clear that GLP-1s may be step-edited before resmetirom.” However, the firm doesn’t think GLP-1s will “eliminate” the market opportunity for Madrigal Pharmaceuticals (MDGL) in NASH, the analyst added. The firm currently estimates “conservative penetration” for resmetirom to get to its $2.3B peak sales estimate in the U.S., the analyst tells investors. Jefferies has Buy ratings on both Madrigal and Lilly shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
- Madrigal, 89bio, Akero slip after Eli Lilly MASH data released
- Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Madrigal to present multiple resmetirom abstracts at EASL Congress
- Paulson buys Carrols, exits SSR Mining in Q1
Questions or Comments about the article? Write to editor@tipranks.com